FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382139166> ?p ?o ?g. }

• W4382139166 abstract "Introduction Second-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings. Nevertheless, in some resource-limited settings, these drugs are not always available. An analysis of the experience with the use of INSTIs in unselected adults living with HIV may be of help to make therapeutic decisions when second-generation INSTIs are not available. This study aimed to evaluate the real-life effectiveness and safety of dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), and raltegravir (RAL) in a large Spanish cohort of HIV-1-infected patients. Methods Real-world study of adults living with HIV who initiated integrase INSTIs DTG, EVG/c, and RAL-based regimens in three settings (ART-naïve patients, ART-switching, and ART-salvage patients). The primary endpoint was the median time to treatment discontinuation after INSTI-based regimen initiation. Proportion of patients experiencing virological failure (VF) (defined as two consecutive viral loads (VL) ≥200 copies/mL at 24 weeks or as a single determination of VL ≥1,000 copies/mL while receiving DTG, EVG/c or RAL, and at least 3 months after INSTI initiation) and time to VF were also evaluated. Results Virological effectiveness of EVG/c- and RAL-based regimens was similar to that of DTG when given as first-line and salvage therapy. Treatment switching for reasons other than virological failure was more frequent in subjects receiving EVG/c and, in particular, RAL. Naïve patients with CD4+ nadir &lt;100 cells/μL were more likely to develop VF, particularly if they initiated RAL or EVG/c. In the ART switching population, initiation of RAL and EVG/c was associated with both VF and INSTI discontinuation. There were no differences in the time to VF and INSTI discontinuation between DTG, EVG/c and RAL. Immunological parameters improved in the three groups and for the three drugs assessed. Safety and tolerability were consistent with expected safety profiles. Discussion Whereas second-generation INSTIs are preferred treatment options worldwide, and DTG is one of the treatment of choices in resource-limited settings, first-generation INSTIs may still provide high virological and immunological effectiveness when DTG is not available." @default.
• W4382139166 created "2023-06-27" @default.
• W4382139166 creator A5000019742 @default.
• W4382139166 creator A5009834773 @default.
• W4382139166 creator A5010065694 @default.
• W4382139166 creator A5012400071 @default.
• W4382139166 creator A5013395065 @default.
• W4382139166 creator A5019841865 @default.
• W4382139166 creator A5025847860 @default.
• W4382139166 creator A5043509211 @default.
• W4382139166 creator A5049140504 @default.
• W4382139166 creator A5049760627 @default.
• W4382139166 creator A5055635751 @default.
• W4382139166 creator A5055739748 @default.
• W4382139166 creator A5060660250 @default.
• W4382139166 creator A5062236640 @default.
• W4382139166 creator A5063841440 @default.
• W4382139166 creator A5068217739 @default.
• W4382139166 creator A5069551708 @default.
• W4382139166 creator A5072944678 @default.
• W4382139166 creator A5076619761 @default.
• W4382139166 creator A5079700165 @default.
• W4382139166 creator A5091097962 @default.
• W4382139166 creator A5091770530 @default.
• W4382139166 date "2023-06-26" @default.
• W4382139166 modified "2023-10-18" @default.
• W4382139166 title "Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study" @default.
• W4382139166 cites W1990925084 @default.
• W4382139166 cites W1993363443 @default.
• W4382139166 cites W2055829400 @default.
• W4382139166 cites W2094811879 @default.
• W4382139166 cites W2122026430 @default.
• W4382139166 cites W2128419295 @default.
• W4382139166 cites W2139430929 @default.
• W4382139166 cites W2145467751 @default.
• W4382139166 cites W2151050670 @default.
• W4382139166 cites W2159328065 @default.
• W4382139166 cites W2333212857 @default.
• W4382139166 cites W2530548126 @default.
• W4382139166 cites W2554692247 @default.
• W4382139166 cites W2556153964 @default.
• W4382139166 cites W2600344958 @default.
• W4382139166 cites W2608989554 @default.
• W4382139166 cites W2728117782 @default.
• W4382139166 cites W2735576184 @default.
• W4382139166 cites W2800677865 @default.
• W4382139166 cites W2903165386 @default.
• W4382139166 cites W2904391316 @default.
• W4382139166 cites W2913317838 @default.
• W4382139166 cites W2922008307 @default.
• W4382139166 cites W2966490059 @default.
• W4382139166 cites W2967602084 @default.
• W4382139166 cites W3089891972 @default.
• W4382139166 cites W3197192948 @default.
• W4382139166 cites W4221004248 @default.
• W4382139166 doi "https://doi.org/10.3389/fcimb.2023.1187999" @default.
• W4382139166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37434782" @default.
• W4382139166 hasPublicationYear "2023" @default.
• W4382139166 type Work @default.
• W4382139166 citedByCount "0" @default.
• W4382139166 crossrefType "journal-article" @default.
• W4382139166 hasAuthorship W4382139166A5000019742 @default.
• W4382139166 hasAuthorship W4382139166A5009834773 @default.
• W4382139166 hasAuthorship W4382139166A5010065694 @default.
• W4382139166 hasAuthorship W4382139166A5012400071 @default.
• W4382139166 hasAuthorship W4382139166A5013395065 @default.
• W4382139166 hasAuthorship W4382139166A5019841865 @default.
• W4382139166 hasAuthorship W4382139166A5025847860 @default.
• W4382139166 hasAuthorship W4382139166A5043509211 @default.
• W4382139166 hasAuthorship W4382139166A5049140504 @default.
• W4382139166 hasAuthorship W4382139166A5049760627 @default.
• W4382139166 hasAuthorship W4382139166A5055635751 @default.
• W4382139166 hasAuthorship W4382139166A5055739748 @default.
• W4382139166 hasAuthorship W4382139166A5060660250 @default.
• W4382139166 hasAuthorship W4382139166A5062236640 @default.
• W4382139166 hasAuthorship W4382139166A5063841440 @default.
• W4382139166 hasAuthorship W4382139166A5068217739 @default.
• W4382139166 hasAuthorship W4382139166A5069551708 @default.
• W4382139166 hasAuthorship W4382139166A5072944678 @default.
• W4382139166 hasAuthorship W4382139166A5076619761 @default.
• W4382139166 hasAuthorship W4382139166A5079700165 @default.
• W4382139166 hasAuthorship W4382139166A5091097962 @default.
• W4382139166 hasAuthorship W4382139166A5091770530 @default.
• W4382139166 hasBestOaLocation W43821391661 @default.
• W4382139166 hasConcept C126322002 @default.
• W4382139166 hasConcept C142462285 @default.
• W4382139166 hasConcept C14430832 @default.
• W4382139166 hasConcept C159047783 @default.
• W4382139166 hasConcept C197934379 @default.
• W4382139166 hasConcept C2776694085 @default.
• W4382139166 hasConcept C2777068322 @default.
• W4382139166 hasConcept C2777302000 @default.
• W4382139166 hasConcept C2778375690 @default.
• W4382139166 hasConcept C2778715236 @default.
• W4382139166 hasConcept C2779502633 @default.
• W4382139166 hasConcept C2780404665 @default.
• W4382139166 hasConcept C2780524789 @default.
• W4382139166 hasConcept C2780775027 @default.
• W4382139166 hasConcept C2781413609 @default.
• W4382139166 hasConcept C2993143319 @default.

• next